Melatonin gummies move from jet lag aid to children’s sleep routine

A safety alert in Australia last year found imported melatonin gummies marketed for children contained far more hormone than their labels claimed—between roughly 112% and 417% of the stated dose, according to testing cited by The Independent. The incident pushed one large online retailer, iHerb, to suspend sales of melatonin gummies to Australia and triggered a warning from the country’s medicines regulator.

Melatonin sits awkwardly between medicine and lifestyle product. In the US it is widely sold over the counter as a dietary supplement, including child-friendly gummies, while in the UK it is generally prescription-only. That split creates a predictable workaround: UK parents who want melatonin for a child often obtain it online or bring it back from abroad, The Independent reports, effectively importing US supplement-market norms into a tighter European prescribing system.

Clinicians quoted in the piece describe melatonin as a hormone that helps signal sleep timing rather than a sedative, and they stress that use in children is typically reserved—when prescribed—for specific groups such as those with autism, ADHD, visual impairment, or other neurodevelopmental conditions that can disrupt sleep. The practical concern is not only whether melatonin “works” in a narrow sense, but whether families end up substituting a gummy for the harder, slower interventions that actually address the cause of insomnia: sleep routines, light exposure, anxiety, screen habits, and household schedules.

The supply chain matters because the consumer product is designed to be easy for children to take. Gummies look and taste like sweets, which raises the risk of accidental ingestion and dosing errors. Regulators’ findings of large discrepancies between labelled and actual content turn that risk from theoretical to arithmetic: parents may believe they are giving a low dose while the child receives something materially higher.

The Independent also describes how social media amplifies demand. Sleep advice is a high-engagement topic, and “optimising” rest lends itself to influencer content and product recommendations. In that environment, parents are pulled toward tools that promise immediate results and can be purchased without a clinical appointment, while the costs of long-term uncertainty—tolerance, dependence on routines that require a pill, or simply not knowing what is in the product—are borne privately, one household at a time.

In the UK, melatonin remains a prescription drug, but the market that supplies it to many families is increasingly the internet. The product that arrives at the door can look like candy, and the label may not match the dose inside.